← Eichor
Condition: Tp53 Y220C Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tp53 Y220C Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06908434A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, R
Phase 1 · 5 location(s) · PMV Pharmaceuticals, Inc · NCT07372625JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Phase 1/Phase 2 · 15 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06386146A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP
Phase 1/Phase 2 · 2 location(s) · Nutshell Therapeutics (Shanghai) Co., LTD. · NCT07060989The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.